⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1309263 | 0.78 | — | — | |
| SCHEMBL8671494 | 0.77 | TAAR1 (0.71) | — | |
| SCHEMBL248034 | 0.74 | — | — | |
| SCHEMBL1309778 | 0.74 | — | — | |
| SCHEMBL6513404 | 0.74 | TAAR1 (0.54) | — | |
| SCHEMBL9855401 | 0.72 | TAAR1 (0.65) | — | |
| SCHEMBL120232 | 0.72 | — | — | |
| SCHEMBL479477 | 0.72 | — | — | |
| SCHEMBL453909 | 0.72 | — | — | |
| SCHEMBL453914 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 342 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117229205-A | Preparation method and pharmaceutical application of phenyl acrylamide RHbDD1 inhibitor | 中国医学科学院基础医学研究所 | 2023-12-15 | — | — | CN | claimed |
| WO-2019118855-A1 | COMPOUNDS AND COMPOSITIONS FOR PREVENTION AND/OR TREATMENT OF CANCER | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2019-06-20 | — | — | WO | claimed |
| US-9139567-B2 | Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-22 | — | — | US | claimed |
| US-20150086497-A1 | Skin Lightening Compositions | ELC MAN LLC (US) | 2015-03-26 | — | — | US | claimed |
| US-20140221373-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-07 | — | — | US | claimed |
| US-20140212365-A9 | SKIN LIGHTENING COMPOSITIONS | NIKI YOKO (JP) | 2014-07-31 | — | — | US | claimed |
| US-20140112877-A1 | SKIN LIGHTENING COMPOSITIONS | NIKI YOKO (JP) | 2014-04-24 | — | — | US | claimed |
| EP-2521531-A2 | SKIN LIGHTENING COMPOSITIONS | ELC Management LLC (US) | 2012-11-14 | — | — | EP | claimed |
| US-20110171149-A1 | Skin Lightening Compositions | ELC MANAGEMENT LLC | 2011-07-14 | — | — | US | claimed |
| WO-2011085015-A2 | SKIN LIGHTENING COMPOSITIONS | ELC MANAGEMENT LLC (US) | 2011-07-14 | — | — | WO | claimed |
| US-6608101-B1 | Inflammatory disorders; 3-(2,4-dimethoxy-5-(thien-2-yl)phenyl)-1-(4-carboxymethoxy-3,5 -dimethoxyphenyl)-2-propen-1-one; | ATHEROGENICS, INC. | 2003-08-19 | — | — | US | claimed |
| EP-1330448-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | Atherogenics, Inc. (US) | 2003-07-30 | — | — | EP | claimed |
| WO-2001098291-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | ATHEROGENICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| EP-0509398-B1 | Quinoxalines, process for their preparation and their use | AVENTIS PHARMA GMBH (DE) | 2001-09-19 | — | — | EP | claimed |
| EP-0728128-B1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE POULENC RORER LTD (GB) | 1998-09-16 | — | — | EP | claimed |
| WO-1998037088-A1 | DERIVATIVES OF CYCLODEPSIPEPTIDE, PF1022 SUBSTANCE | MEIJI SEIKA KAISHA LTD. (JP) | 1998-08-27 | — | — | WO | claimed |
| EP-0728128-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1996-08-28 | — | — | EP | claimed |
| WO-1995013262-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1995-05-18 | — | — | WO | claimed |
| US-4450164-A | ANTIULCER AND ANTISECRETORY AGENTS | SCHERING CORPORATION (US) | 1984-05-22 | — | — | US | claimed |
| US-4409226-A | ANTIULCER AGENTS | SCHERING CORPORATION (US) | 1983-10-11 | — | — | US | claimed |